Mass General Brigham is an integrated academic health care system that provides a comprehensive range of medical services across its various facilities. The organization prioritizes patient care, research, and education, while also advancing innovative solutions in medicine. As a principal teaching affiliate of Harvard Medical School, Mass General Brigham plays a vital role in biomedical research, contributing to the development of new medical technologies and treatments. By fostering collaboration between its medical facilities and academic partners, the organization aims to enhance healthcare delivery and improve patient outcomes.
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.
Rippl Care
Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
Tuesday Health
Venture Round in 2024
Tuesday Health empowers lives through supportive care by easing the symptoms and stress of serious illness.
InStride Health
Series B in 2024
InStride Health is an outpatient care platform focused on delivering evidence-based treatment for pediatric anxiety and obsessive-compulsive disorder (OCD). The company offers a tailored virtual care journey that includes individual and group therapy, coaching, and medication management, all facilitated by a coordinated team of psychiatrists, therapists, and coaches. This approach ensures that children and teenagers receive effective, accessible, and affordable care, keeping them engaged throughout the treatment process. By prioritizing evidence-based practices, InStride Health aims to enhance the mental well-being of young patients and their families.
Nocion Therapeutics
Series B in 2024
Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.
Abridge
Series C in 2024
Abridge Inc. is a healthcare technology company founded in September 1999, focused on enhancing communication in medical settings through innovative tools. The company utilizes generative AI to automate the transcription and summarization of patient-clinician conversations, converting these interactions into structured clinical notes in real-time. This platform integrates seamlessly with Electronic Health Record (EHR) systems, significantly reducing the need for manual note-taking. By generating clear and understandable summaries, Abridge improves patient comprehension of medical discussions and ensures that relevant documentation is accurately recorded in patient files. Additionally, the company emphasizes data security and patient privacy, adhering to healthcare regulations while providing a customizable interface that caters to individual patient needs.
Claris Biotherapeutics
Series A in 2024
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.
ROME Therapeutics
Series B in 2023
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.
Abcuro
Series B in 2023
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.
Violet Therapeutics
Venture Round in 2023
Violet Therapeutics is a pre-clinical stage company focused on drug discovery for central nervous system (CNS) diseases. It utilizes a unique platform that employs barcoded viral tracing to identify, map, and analyze cellular connectomes at a large scale. This innovative approach allows for detailed insights into cell-cell interactions at the single-cell level, which is crucial for advancing treatments for neuroinflammation. Co-founded by Mass General Brigham Ventures and researchers from Brigham & Women’s Hospital, Violet Therapeutics is dedicated to developing novel therapeutic targets that can lead to significant breakthroughs in CNS disease treatment.
Mediar Therapeutics
Series A in 2023
Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.
CodaMetrix
Series A in 2023
CodaMetrix is a developer of an AI-powered platform focused on automating healthcare revenue cycle management and medical coding. The platform utilizes machine learning, deep learning, and natural language processing to accurately translate clinical notes into billing and diagnostic codes. This automation not only meets coding requirements but also significantly reduces the workload for human coders. By continuously learning from clinical evidence within electronic health records and drawing from a comprehensive library of data points from national health systems, CodaMetrix enhances coding efficiency and quality, ultimately allowing healthcare providers to optimize their operations.
Garuda Therapeutics
Series B in 2023
Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.
Amolyt Pharma
Series C in 2023
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.
FireCyte Therapeutics
Seed Round in 2023
FireCyte Therapeutics is focused on developing innovative treatments for progressive neurodegenerative eye diseases by targeting the roles of microglia and neuroinflammation. The company utilizes novel protein constructs designed to interact with both microglia and neurons, aiming to reduce harmful neuroinflammatory processes while promoting neuroprotection. This approach addresses significant unmet medical needs in conditions such as glaucoma and age-related macular degeneration, providing healthcare professionals with new therapeutic options for managing these challenging diseases.
InStride Health
Venture Round in 2022
InStride Health is an outpatient care platform focused on delivering evidence-based treatment for pediatric anxiety and obsessive-compulsive disorder (OCD). The company offers a tailored virtual care journey that includes individual and group therapy, coaching, and medication management, all facilitated by a coordinated team of psychiatrists, therapists, and coaches. This approach ensures that children and teenagers receive effective, accessible, and affordable care, keeping them engaged throughout the treatment process. By prioritizing evidence-based practices, InStride Health aims to enhance the mental well-being of young patients and their families.
Rippl Care
Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
Photys Therapeutics
Series A in 2022
Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.
Carta Healthcare
Series B in 2022
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
SwanBio Therapeutics
Series B in 2022
SwanBio Therapeutics is dedicated to developing therapeutic technologies aimed at treating neurological diseases. The company specializes in creating and commercializing genetically defined therapies tailored for neurological disorders. Its innovative approach seeks to provide significant clinical efficacy, particularly for conditions such as Adrenomyeloneuropathy (AMN) and other related diseases, thereby supporting healthcare organizations in their efforts to improve patient outcomes.
DexCare
Series B in 2022
DexCare is a Seattle-based company founded in 2021 that specializes in providing a platform-as-a-service solution for managing health system capacity and demand across various lines of care. The company's platform aims to transform traditional patient-to-provider relationships into scalable digital experiences, thereby increasing revenue from new patients while reducing acquisition costs. By optimizing access to healthcare services, DexCare helps healthcare institutions generate new patients, enhance satisfaction, achieve cost savings, and ensure that patients receive timely and effective care.
Garuda Therapeutics
Series A in 2021
Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.
Amolyt Pharma
Series B in 2021
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.
ROME Therapeutics
Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.
Lyndra Therapeutics
Series C in 2021
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.
Affinia Therapeutics
Series B in 2021
Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.
Carta Healthcare
Series A in 2021
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
SeQure DX
Venture Round in 2021
SeQure Dx specializes in providing safety data related to CRISPR gene editing therapies, focusing on both on-target and off-target effects. The company develops genomics diagnostic technologies that facilitate target profiling for gene editing, supporting the discovery, clinical development, and diagnostic processes. Its core technologies are designed to identify potential off-target sites prior to the initiation of therapy, ensuring comprehensive confirmation of actual genetic edits. This capability empowers gene editing therapeutics developers, physicians, and patients by enhancing the safety and efficacy of gene editing treatments.
Abcuro
Series A in 2021
Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.
CustomSurg
Grant in 2020
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Scorpion Therapeutics
Series A in 2020
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.
Walden Biosciences
Series A in 2020
Walden Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative treatments for individuals with kidney disease. Founded by experts in renal disease, the company employs a systems-based approach to address the complex interplay between the pathology and biology of kidney conditions. Walden Biosciences targets specific biomarkers and enzymes, such as suPAR, an inflammatory marker linked to kidney function, and Dynamin, which plays a role in podocyte regeneration. Their goal is to create effective therapies for various kidney diseases, including chronic kidney disease and acute kidney injury, providing targeted treatment options that act directly at the site of drug action.
ZielBio
Series A in 2019
ZielBio, Inc. is a biotechnology company focused on identifying high-value disease targets and developing therapeutic interventions to enhance patient outcomes. The company is based in Charlottesville, Virginia, and utilizes its proprietary drug discovery platform, Zielfind, which integrates functional high-throughput screening with large content data analytics to pinpoint valuable targets. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody designed to target cell surface plectin, a significant player in various cancers including ovarian, pancreatic, lung, and colorectal cancer. Founded in 2010, ZielBio aims to transform disease treatment through innovative therapeutic approaches.
Lyndra Therapeutics
Series B in 2019
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.
Mediar Therapeutics
Seed Round in 2019
Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.
QurAlis
Seed Round in 2018
QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.
Pykus Therapeutics
Seed Round in 2018
Pykus Therapeutics, Inc. is a medical technology company based in Boston, Massachusetts, founded in 2016 by ophthalmology residents. The company specializes in developing a dissolvable intraocular surgical device designed to enhance the experience of patients undergoing retinal surgery. Its innovative polymer-based hydrogel serves as a replacement for traditional intraocular gas, which can impose significant burdens on patients, such as the need for face-down positioning and prolonged periods of visual impairment. By utilizing this biodegradable hydrogel, Pykus Therapeutics aims to improve surgical outcomes and patient comfort, facilitating a faster and more comfortable recovery process after retinal procedures.
Lyndra Therapeutics
Series A in 2017
Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.
Massachusetts Eye and Ear
Acquisition in 2017
Massachusetts Eye and Ear is a specialized hospital located in Boston, focusing on the research, education, and treatment of conditions related to the eye and ear. Established in 1824, the institution operates as a non-profit entity dedicated to advancing the field of ophthalmology and otolaryngology. It is supported by the Foundation of Massachusetts Eye & Ear, which raises funds to benefit the hospital's mission and ensures that resources are allocated effectively for various initiatives. The foundation plays a crucial role in managing assets and providing financial support for the hospital's research and patient care programs. Through its comprehensive approach, Massachusetts Eye and Ear aims to improve patient outcomes and contribute to advancements in medical knowledge related to eye and ear health.
Health Catalyst
Series D in 2015
Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.
T2 Biosystems
Series D in 2011
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
T2 Biosystems
Series C in 2010
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
T2 Biosystems
Series B in 2008
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
Provasculon
Series A in 2008
Provasculon is a biotechnology company focused on developing novel therapeutic proteins aimed at healing organs damaged by ischemia. Founded based on the discoveries of Richard Lee, MD, and Vincent Segers, MD, both affiliated with Brigham and Women's Hospital, Provasculon specializes in innovative applications of Stromal Cell-Derived Factor-1 (SDF-1). The company's lead therapeutic protein shows promise in restoring the function of hearts severely affected by ischemic conditions, potentially bringing them back to near normal performance. Through its research and development efforts, Provasculon seeks to address critical medical needs in the treatment of ischemic organ damage.
Freedom2
Series A in 2007
Freedom2 is a company specializing in innovative tattoo technology, aimed at providing a safer and more efficient solution for tattoo removal. Founded nearly a decade ago, the company developed the Particle Encapsulation and Enhancement (P2E) Platform, which utilizes microscopic bioabsorbable pigments and dyes encapsulated in a biocompatible polymer. This unique approach allows for the creation of tattoos that can be easily removed through a single standard laser treatment. During this procedure, the laser breaks the polymer beads, enabling the body to naturally expel the trapped dye. By offering a more effective alternative to traditional tattoo removal methods, Freedom2 addresses the common concerns associated with permanent tattoos, emphasizing personal expression while providing an option for future removal.
GlobeImmune
Series B in 2005
GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.
Radianse
Venture Round in 2004
Radianse provides intelligent solutions for businesses with their real-time tracking services. Their advanced software automatically collects and processes a variety of live data on any asset. The situation history is recorded and easily accessible through their Radianse Awareness Suite from any web-enabled device. Their mission is to improve the way businesses operate by providing accessible, affordable, andcustomized solutions that automatically integrate data sources into real-time actionable intelligence. They aim to be the market leader in the providing of situation awareness coupled with actionable intelligence. Their goal is to deliver innovative, technology-based applications that allow their customers to manage their resources, control costs, increase revenue opportunities, and improve overall operational efficiency. Radianse has achieved significant milestones in developing cutting-edge algorithms and methodologies to deliver reliable products with superior accuracy and performance. All of their products are covered by one or more patents with additional U.S. and international patents pending. Radianse is committed to constantly innovating and evolving. They began as an engineering organization focused on Radio Frequency Identification (RFID) technology-based solutions. Their aim was to automatically and continuously monitor high-value hospital assets. Radianse now works with many clients from various industries. Radianse remains focused on being committed to innovative research and development. Radianse is applying its leadership and extensive networking knowledge along with inventive technology designs to launch new and advanced applications. They are committed to innovation and delivering intelligent solutions for any industry.
Carta Healthcare
Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.